Peptide And Oligonucleotide CDMO Market Outlook For 2026–2030 Covering Growth Drivers And Industry Trends
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Will The Market Value Of The Peptide And Oligonucleotide CDMO Market Progress Between 2026 And 2030?
The size of the peptide and oligonucleotide cdmo market has expanded significantly over recent years. It is projected to further increase from $2.42 billion in 2025 to $2.7 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. This historical expansion can be ascribed to several factors, including the growth in peptide-based therapeutics, the increasing complexity of synthetic oligonucleotides, the limited in-house manufacturing capabilities of drug developers, rising regulatory compliance requirements, and the early adoption of antisense and peptide drugs.
The peptide and oligonucleotide CDMO market size is poised for substantial growth in the upcoming years. It is projected to expand to $4.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.5%. This anticipated growth during the forecast period is driven by factors such as the expansion of oligonucleotide therapeutics pipelines, increasing investment in rare disease and oncology medications, a rising demand for swift clinical trial material production, a growing preference for specialized CDMO collaborations, and advancements in solid-phase synthesis technologies. Significant trends for the forecast period include an increase in the outsourcing of peptide and oligonucleotide manufacturing, a growing need for cGMP-compliant complex molecule production, the expansion of comprehensive end-to-end development and manufacturing services, an amplified focus on high-potency and high-purity therapeutics, and a greater adoption of scalable and flexible manufacturing platforms.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15892&type=smp
Which Important Drivers Are Guiding The Peptide And Oligonucleotide CDMO Market Growth?
The expanding adoption of personalized medicine is anticipated to drive the growth of the peptide and oligonucleotide CDMO markets moving forward. Personalized medicine refers to a healthcare approach that tailors medical decisions and treatments to individual characteristics, including genetics, environment, and lifestyle. The increasing uptake of personalized medicine is attributed to several factors such as advancements in genomic technologies, an enhanced understanding of disease mechanisms at the molecular level, and the demand for more effective and targeted treatment options customized to individual patients’ genetic profiles and medical histories. Peptide and oligonucleotide contract development and manufacturing organizations (CDMOs) play a critical role in personalized medicine by producing customized therapeutic peptides and oligonucleotides specifically for individual patient needs. For instance, in February 2024, according to the Personalized Medicine Coalition, a UK-based organization promoting the adoption of personalized medicine, the Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) approved 16 new personalized treatments for rare disease patients, an increase from 6 in 2022. Therefore, the growing adoption of personalized medicine is fueling the growth of the peptide and oligonucleotide CDMO market.
What Are The Different Segment Types In The Peptide And Oligonucleotide CDMO Market Segment Breakdown?
The peptide and oligonucleotide cdmo market covered in this report is segmented –
1) By Product: Peptides, Oligonucleotides
2) By Service Type: Contract Development, Contract Manufacturing,
3) By Application: Therapeutics, Research Applications, Diagnostics, Other Applications
4) By End User: Biopharmaceutical Companies, Pharmaceutical Companies, Research Institutes, Academic and Government Organizations, Other End Users
Subsegments:
1) By Peptides: Active Pharmaceutical Ingredients (Apis), Peptide Drug Products, Peptide Synthesis And Manufacturing Services
2) By Oligonucleotides: Antisense Oligonucleotides, Sirna And Mrna Oligonucleotides, Oligonucleotide Synthesis And Manufacturing Services
Which Trends Are Contributing To Changes In The Peptide And Oligonucleotide CDMO Market?
Leading firms within the peptide and oligonucleotide CDMO market are prioritizing the formation of strategic alliances to improve their service provisions, broaden their technological capacities, and extend their presence in the market. Such partnerships, centered on peptide development and production, represent collaborative arrangements between two entities dedicated to creating and producing therapeutics derived from peptides. A notable example is the collaboration in May 2023, where PolyPeptide Group AG, a US-headquartered contract development and manufacturing organization (CDMO), formed a partnership with Numaferm GmbH, a biotechnology firm based in Germany, for the purpose of peptide development and production. This alliance seeks to leverage PolyPeptide’s cGMP manufacturing capabilities and market entry, alongside Numaferm’s specialized knowledge in sustainable peptide manufacturing and biochemical production platforms. The collaboration’s primary objective is to jointly investigate the creation of appropriate peptide candidates, with the ultimate aim of achieving more environmentally friendly production of active pharmaceutical ingredients (APIs) based on peptides.
Who Are The Well-Known Companies In The Peptide And Oligonucleotide CDMO Market?
Major companies operating in the peptide and oligonucleotide cdmo market are Thermo Fisher Scientific Inc., Merck KGaA, Ajinomoto Co. Inc., Lonza Group Ag, Wuxi Apptec Co. Ltd., Catalent Inc., Piramal Pharma Ltd, Curia Global Inc., Almac Group, Euroapi SA., CordenPharma International, Bachem Holding AG, Genscript Biotech Corporation, PolyPeptide Group, Rentschler Biopharma SE, Ambiopharm Inc, ScinoPharm, Senn Chemicals AG, Aurigene Pharmaceutical Services, Creative Peptides, Sylentis S.A.
Get The Full Peptide And Oligonucleotide CDMO Market Report:
Which Region Holds The Highest Market Share In The Peptide And Oligonucleotide CDMO Market?
North America was the largest region in the peptide and oligonucleotide CDMO market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the peptide and oligonucleotide cdmo market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Peptide And Oligonucleotide CDMO Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Peptide And Oligonucleotide CDMO Market 2026, By The Business Research Company
Peptide And Oligonucleotide Cdmo Market Report 2026
Oligonucleotides Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/oligonucleotides-therapy-global-market-report
Peptide Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
